145 related articles for article (PubMed ID: 38830971)
21. Evaluation of Programmed Death - Ligand 1 (Pd-L1) Expression in Head and Neck Squamous Cell Carcinoma.
Unnikrishnan A; Basavaraj V
Iran J Pathol; 2023; 18(2):193-201. PubMed ID: 37600575
[TBL] [Abstract][Full Text] [Related]
22. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
23. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
24. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
25. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
26. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
27. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
[TBL] [Abstract][Full Text] [Related]
28. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images.
Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW
Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695
[TBL] [Abstract][Full Text] [Related]
29. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
30. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.
Ock CY; Kim S; Keam B; Kim S; Ahn YO; Chung EJ; Kim JH; Kim TM; Kwon SK; Jeon YK; Jung KC; Kim DW; Wu HG; Sung MW; Heo DS
Oncotarget; 2017 Nov; 8(58):97920-97927. PubMed ID: 29228662
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.
Crosta S; Boldorini R; Bono F; Brambilla V; Dainese E; Fusco N; Gianatti A; L'Imperio V; Morbini P; Pagni F
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466794
[TBL] [Abstract][Full Text] [Related]
32. Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study.
Guerini Rocco E; Eccher A; Girolami I; Graziano P; Fontanini G; Vigliar E; Troncone G; Barberis M; Morbini P; Martini M
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204568
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
34. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
35. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Italiano A; Cassier PA; Lin CC; Alanko T; Peltola KJ; Gazzah A; Shiah HS; Calvo E; Cervantes A; Roda D; Tosi D; Gao B; Millward M; Warburton L; Tanner M; Englert S; Lambert S; Parikh A; Afar DE; Vosganian G; Moreno V
Cancer Immunol Immunother; 2022 Feb; 71(2):417-431. PubMed ID: 34216247
[TBL] [Abstract][Full Text] [Related]
36. Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors.
Leddon JL; Chirra M; Frankart AJ; Agrawal A; Roof L; Trotier D; Shaikh H; Stone T; Jandarov R; Takiar V; Wise-Draper TM
Laryngoscope; 2021 Jul; 131(7):E2413-E2419. PubMed ID: 33609046
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression in fine-needle aspiration cell blocks of head and neck squamous-cell carcinoma and its cytohistological concordance.
Lou SSK; Ruff H; MacDonald S; Smith SM; Cheung CC
Diagn Cytopathol; 2024 Mar; 52(3):163-170. PubMed ID: 38095142
[TBL] [Abstract][Full Text] [Related]
38. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
39. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for head and neck cancer: Recent advances and future directions.
Cramer JD; Burtness B; Ferris RL
Oral Oncol; 2019 Dec; 99():104460. PubMed ID: 31683169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
